Drugmakers seek incentives to develop antibiotics to fight 'superbugs'
They also call for diagnostic tests so that antibacterial drugs are not used needlessly
New York
MORE than 80 pharmaceutical and diagnostic companies from around the world are calling for new economic models to spur development of badly needed new antibiotics and to fight the rising global threat of drug-resistant "superbugs."
In a declaration that is being released on Thursday at the World Economic Forum in Davos, Switzerland, the companies say that governments must work with companies to fight the problem of antimicrobial resistance, in which many germs are no longer killed by common antibiotics and in some cases even by last-ditch options, turning once-treatable infections into life-threatening events.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
EU toughens rules on Chinese fashion retailer Shein
Best World under fire from shareholders at AGM over dividends, director salaries
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue